AU2008329070B2 - MCP-I binding nucleic acids and use thereof - Google Patents

Info

Publication number

AU2008329070B2

AU2008329070B2 AU2008329070A AU2008329070A AU2008329070B2 AU 2008329070 B2 AU2008329070 B2 AU 2008329070B2 AU 2008329070 A AU2008329070 A AU 2008329070A AU 2008329070 A AU2008329070 A AU 2008329070A AU 2008329070 B2 AU2008329070 B2 AU 2008329070B2

Authority

AU

Australia

Prior art keywords

nucleotide sequence

nucleic acid

stretch box

mcp

group

Prior art date

2007-11-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 424
• 102000039446 nucleic acids Human genes 0.000 title claims abstract description 404
• 108020004707 nucleic acids Proteins 0.000 title claims abstract description 404
• 238000009739 binding Methods 0.000 title claims abstract description 173
• 230000027455 binding Effects 0.000 title claims abstract description 172
• 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 title abstract 2
• 239000003814 drug Substances 0.000 claims abstract description 93
• 238000011282 treatment Methods 0.000 claims abstract description 84
• 230000002265 prevention Effects 0.000 claims abstract description 19
• 239000002773 nucleotide Substances 0.000 claims description 281
• 125000003729 nucleotide group Chemical group 0.000 claims description 266
• 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 102
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 73
• 201000010099 disease Diseases 0.000 claims description 63
• 238000000034 method Methods 0.000 claims description 61
• 241001465754 Metazoa Species 0.000 claims description 49
• 102000046768 human CCL2 Human genes 0.000 claims description 49
• 241000282414 Homo sapiens Species 0.000 claims description 45
• 230000004048 modification Effects 0.000 claims description 45
• 238000012986 modification Methods 0.000 claims description 45
• 239000003018 immunosuppressive agent Substances 0.000 claims description 40
• 208000005777 Lupus Nephritis Diseases 0.000 claims description 35
• 229940125721 immunosuppressive agent Drugs 0.000 claims description 35
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 34
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 34
• 239000008194 pharmaceutical composition Substances 0.000 claims description 27
• 230000001684 chronic effect Effects 0.000 claims description 25
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 24
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 23
• 230000002685 pulmonary effect Effects 0.000 claims description 21
• 229960004397 cyclophosphamide Drugs 0.000 claims description 20
• 229960003957 dexamethasone Drugs 0.000 claims description 19
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 19
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 17
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 17
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 14
• 229960004866 mycophenolate mofetil Drugs 0.000 claims description 14
• 229960002586 roflumilast Drugs 0.000 claims description 13
• MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 13
• 208000019693 Lung disease Diseases 0.000 claims description 10
• 206010006451 bronchitis Diseases 0.000 claims description 10
• 230000002792 vascular Effects 0.000 claims description 8
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 7
• 102100024502 Ceramide glucosyltransferase Human genes 0.000 claims description 7
• 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 7
• 101000981050 Homo sapiens Ceramide glucosyltransferase Proteins 0.000 claims description 7
• 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims description 7
• 206010057481 Lupus pneumonitis Diseases 0.000 claims description 7
• 208000007451 chronic bronchitis Diseases 0.000 claims description 7
• 206010014561 Emphysema Diseases 0.000 claims description 6
• 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims description 5
• 206010021143 Hypoxia Diseases 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 208000015669 capillary disease Diseases 0.000 claims description 4
• 230000003073 embolic effect Effects 0.000 claims description 4
• 208000019622 heart disease Diseases 0.000 claims description 4
• 208000018875 hypoxemia Diseases 0.000 claims description 4
• 230000001732 thrombotic effect Effects 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
• 108010036949 Cyclosporine Proteins 0.000 claims description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
• 229960002170 azathioprine Drugs 0.000 claims description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
• 229960004630 chlorambucil Drugs 0.000 claims description 2
• 229960001265 ciclosporin Drugs 0.000 claims description 2
• 229930182912 cyclosporin Natural products 0.000 claims description 2
• 229960001967 tacrolimus Drugs 0.000 claims description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
• 208000017667 Chronic Disease Diseases 0.000 abstract description 46
• 208000014085 Chronic respiratory disease Diseases 0.000 abstract description 19
• 208000020832 chronic kidney disease Diseases 0.000 abstract description 13
• 201000000596 systemic lupus erythematosus Diseases 0.000 abstract description 11
• 102000000018 Chemokine CCL2 Human genes 0.000 description 242
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 239
• 241000699670 Mus sp. Species 0.000 description 149
• 229920001223 polyethylene glycol Polymers 0.000 description 148
• 108091027076 Spiegelmer Proteins 0.000 description 112
• 239000002202 Polyethylene glycol Substances 0.000 description 84
• 238000001514 detection method Methods 0.000 description 80
• 210000004027 cell Anatomy 0.000 description 68
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 52
• 239000000523 sample Substances 0.000 description 52
• 210000002540 macrophage Anatomy 0.000 description 50
• 238000003556 assay Methods 0.000 description 49
• 108091023037 Aptamer Proteins 0.000 description 39
• 206010061218 Inflammation Diseases 0.000 description 34
• 230000004054 inflammatory process Effects 0.000 description 34
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 32
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 32
• 230000000694 effects Effects 0.000 description 32
• 102100023688 Eotaxin Human genes 0.000 description 31
• 238000009396 hybridization Methods 0.000 description 31
• 210000004072 lung Anatomy 0.000 description 30
• 241001529936 Murinae Species 0.000 description 29
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 28
• 101710139422 Eotaxin Proteins 0.000 description 28
• 239000000872 buffer Substances 0.000 description 28
• 239000011575 calcium Substances 0.000 description 28
• 230000035605 chemotaxis Effects 0.000 description 28
• 230000001434 glomerular Effects 0.000 description 28
• 210000003734 kidney Anatomy 0.000 description 28
• 239000003981 vehicle Substances 0.000 description 28
• 102000019034 Chemokines Human genes 0.000 description 27
• 108010012236 Chemokines Proteins 0.000 description 27
• 230000002829 reductive effect Effects 0.000 description 27
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
• 108010055204 Chemokine CCL8 Proteins 0.000 description 26
• 241000700159 Rattus Species 0.000 description 26
• 230000014509 gene expression Effects 0.000 description 26
• 239000002158 endotoxin Substances 0.000 description 25
• 230000003993 interaction Effects 0.000 description 25
• 229920006008 lipopolysaccharide Polymers 0.000 description 25
• 150000001875 compounds Chemical class 0.000 description 24
• 208000033679 diabetic kidney disease Diseases 0.000 description 24
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 23
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 23
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 23
• 229940079593 drug Drugs 0.000 description 23
• 108010055124 Chemokine CCL7 Proteins 0.000 description 22
• 102100023702 C-C motif chemokine 13 Human genes 0.000 description 21
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
• 238000002347 injection Methods 0.000 description 21
• 239000007924 injection Substances 0.000 description 21
• 101710112613 C-C motif chemokine 13 Proteins 0.000 description 20
• 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 20
• 229940124597 therapeutic agent Drugs 0.000 description 20
• 210000001519 tissue Anatomy 0.000 description 20
• 238000002648 combination therapy Methods 0.000 description 19
• 239000000243 solution Substances 0.000 description 19
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
• 210000001616 monocyte Anatomy 0.000 description 18
• 230000001225 therapeutic effect Effects 0.000 description 18
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 17
• 230000001363 autoimmune Effects 0.000 description 17
• 108090000623 proteins and genes Proteins 0.000 description 17
• 230000009467 reduction Effects 0.000 description 17
• 206010018364 Glomerulonephritis Diseases 0.000 description 16
• 210000001744 T-lymphocyte Anatomy 0.000 description 16
• 229960002685 biotin Drugs 0.000 description 16
• 235000020958 biotin Nutrition 0.000 description 16
• 239000011616 biotin Substances 0.000 description 16
• 238000000338 in vitro Methods 0.000 description 16
• 235000018102 proteins Nutrition 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 16
• 238000010379 pull-down assay Methods 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 238000010494 dissociation reaction Methods 0.000 description 15
• 230000005593 dissociations Effects 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 230000007115 recruitment Effects 0.000 description 15
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 14
• 238000010168 coupling process Methods 0.000 description 14
• 238000005859 coupling reaction Methods 0.000 description 14
• 230000006378 damage Effects 0.000 description 14
• 230000002757 inflammatory effect Effects 0.000 description 14
• 206010025135 lupus erythematosus Diseases 0.000 description 14
• 239000000203 mixture Substances 0.000 description 14
• 210000000440 neutrophil Anatomy 0.000 description 14
• 239000013543 active substance Substances 0.000 description 13
• 230000000295 complement effect Effects 0.000 description 13
• 230000008878 coupling Effects 0.000 description 13
• 208000017169 kidney disease Diseases 0.000 description 13
• 239000005557 antagonist Substances 0.000 description 12
• 239000008103 glucose Substances 0.000 description 12
• 239000013641 positive control Substances 0.000 description 12
• 238000002560 therapeutic procedure Methods 0.000 description 12
• 150000001412 amines Chemical class 0.000 description 11
• 150000001413 amino acids Chemical class 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 206010012601 diabetes mellitus Diseases 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 230000002062 proliferating effect Effects 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 208000037816 tissue injury Diseases 0.000 description 11
• 108010090804 Streptavidin Proteins 0.000 description 10
• 208000006673 asthma Diseases 0.000 description 10
• 238000003745 diagnosis Methods 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 231100000673 dose–response relationship Toxicity 0.000 description 10
• 238000005259 measurement Methods 0.000 description 10
• 108020004999 messenger RNA Proteins 0.000 description 10
• 239000013642 negative control Substances 0.000 description 10
• 238000009097 single-agent therapy Methods 0.000 description 10
• 235000002639 sodium chloride Nutrition 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
• 239000012981 Hank's balanced salt solution Substances 0.000 description 9
• 206010035664 Pneumonia Diseases 0.000 description 9
• 230000001154 acute effect Effects 0.000 description 9
• 210000001185 bone marrow Anatomy 0.000 description 9
• 229910052791 calcium Inorganic materials 0.000 description 9
• 230000002860 competitive effect Effects 0.000 description 9
• 238000012606 in vitro cell culture Methods 0.000 description 9
• 230000006320 pegylation Effects 0.000 description 9
• 230000003389 potentiating effect Effects 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 8
• 108020004414 DNA Proteins 0.000 description 8
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
• 241000283973 Oryctolagus cuniculus Species 0.000 description 8
• 230000006399 behavior Effects 0.000 description 8
• 230000009286 beneficial effect Effects 0.000 description 8
• 230000003247 decreasing effect Effects 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 206010061989 glomerulosclerosis Diseases 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 210000000265 leukocyte Anatomy 0.000 description 8
• -1 poly(ethylene glycole) Polymers 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 230000002861 ventricular Effects 0.000 description 8
• 208000006029 Cardiomegaly Diseases 0.000 description 7
• 102000009410 Chemokine receptor Human genes 0.000 description 7
• 108050000299 Chemokine receptor Proteins 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 7
• 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 7
• 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 7
• 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 206010029164 Nephrotic syndrome Diseases 0.000 description 7
• 102100036154 Platelet basic protein Human genes 0.000 description 7
• 229920002472 Starch Polymers 0.000 description 7
• 208000027418 Wounds and injury Diseases 0.000 description 7
• 230000000903 blocking effect Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 238000004422 calculation algorithm Methods 0.000 description 7
• 231100000749 chronicity Toxicity 0.000 description 7
• 238000011156 evaluation Methods 0.000 description 7
• 239000012530 fluid Substances 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000003862 glucocorticoid Substances 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 230000008595 infiltration Effects 0.000 description 7
• 238000001764 infiltration Methods 0.000 description 7
• 208000014674 injury Diseases 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 239000003550 marker Substances 0.000 description 7
• 239000011159 matrix material Substances 0.000 description 7
• 230000005012 migration Effects 0.000 description 7
• 238000013508 migration Methods 0.000 description 7
• 230000007170 pathology Effects 0.000 description 7
• 230000000144 pharmacologic effect Effects 0.000 description 7
• 229940068196 placebo Drugs 0.000 description 7
• 239000000902 placebo Substances 0.000 description 7
• 230000036470 plasma concentration Effects 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 235000019698 starch Nutrition 0.000 description 7
• 238000010254 subcutaneous injection Methods 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 230000003442 weekly effect Effects 0.000 description 7
• 108090001008 Avidin Proteins 0.000 description 6
• 102000001902 CC Chemokines Human genes 0.000 description 6
• 108010040471 CC Chemokines Proteins 0.000 description 6
• 241000282693 Cercopithecidae Species 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 235000001014 amino acid Nutrition 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 208000037976 chronic inflammation Diseases 0.000 description 6
• 230000006020 chronic inflammation Effects 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 239000003246 corticosteroid Substances 0.000 description 6
• 229960001334 corticosteroids Drugs 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 231100000517 death Toxicity 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 208000008423 pleurisy Diseases 0.000 description 6
• 230000000750 progressive effect Effects 0.000 description 6
• 210000001147 pulmonary artery Anatomy 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 239000007929 subcutaneous injection Substances 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 210000002700 urine Anatomy 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• 241000282465 Canis Species 0.000 description 5
• 108010055166 Chemokine CCL5 Proteins 0.000 description 5
• 231100000491 EC50 Toxicity 0.000 description 5
• 208000029523 Interstitial Lung disease Diseases 0.000 description 5
• 208000004852 Lung Injury Diseases 0.000 description 5
• 206010035742 Pneumonitis Diseases 0.000 description 5
• 206010069363 Traumatic lung injury Diseases 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 238000009510 drug design Methods 0.000 description 5
• 210000003979 eosinophil Anatomy 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 230000005284 excitation Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 210000002865 immune cell Anatomy 0.000 description 5
• 238000012744 immunostaining Methods 0.000 description 5
• 230000001506 immunosuppresive effect Effects 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 210000004969 inflammatory cell Anatomy 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 230000003907 kidney function Effects 0.000 description 5
• 231100000515 lung injury Toxicity 0.000 description 5
• QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 5
• QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 5
• 201000008383 nephritis Diseases 0.000 description 5
• 230000004962 physiological condition Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 5
• 238000003753 real-time PCR Methods 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000002784 sclerotic effect Effects 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 229940037128 systemic glucocorticoids Drugs 0.000 description 5
• 230000035488 systolic blood pressure Effects 0.000 description 5
• VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 4
• 238000006677 Appel reaction Methods 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 101150052909 CCL2 gene Proteins 0.000 description 4
• 108050006947 CXC Chemokine Proteins 0.000 description 4
• 102000019388 CXC chemokine Human genes 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
• 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 4
• 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 4
• 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 4
• 206010065673 Nephritic syndrome Diseases 0.000 description 4
• 101710163270 Nuclease Proteins 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 208000020193 Pulmonary artery hypoplasia Diseases 0.000 description 4
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
• 102100040247 Tumor necrosis factor Human genes 0.000 description 4
• 229910052770 Uranium Inorganic materials 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 230000000996 additive effect Effects 0.000 description 4
• 238000000540 analysis of variance Methods 0.000 description 4
• 230000005784 autoimmunity Effects 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 230000001054 cortical effect Effects 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 229940039227 diagnostic agent Drugs 0.000 description 4
• 239000000032 diagnostic agent Substances 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 230000029142 excretion Effects 0.000 description 4
• 230000024924 glomerular filtration Effects 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• 229960003444 immunosuppressant agent Drugs 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 230000004199 lung function Effects 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 201000001268 lymphoproliferative syndrome Diseases 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 210000005087 mononuclear cell Anatomy 0.000 description 4
• 108010087904 neutravidin Proteins 0.000 description 4
• 230000000414 obstructive effect Effects 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 230000008756 pathogenetic mechanism Effects 0.000 description 4
• 210000005259 peripheral blood Anatomy 0.000 description 4
• 239000011886 peripheral blood Substances 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 239000011148 porous material Substances 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 239000013558 reference substance Substances 0.000 description 4
• 229910052709 silver Inorganic materials 0.000 description 4
• 239000004332 silver Substances 0.000 description 4
• 206010040882 skin lesion Diseases 0.000 description 4
• 231100000444 skin lesion Toxicity 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 230000000451 tissue damage Effects 0.000 description 4
• 231100000827 tissue damage Toxicity 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• BICGOULMPJLRQV-MYINAIGISA-N 1-[(2s,4s,5r)-2-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(Br)N1C(=O)NC(=O)C=C1 BICGOULMPJLRQV-MYINAIGISA-N 0.000 description 3
• 108020004463 18S ribosomal RNA Proteins 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 108010088751 Albumins Proteins 0.000 description 3
• 102000009027 Albumins Human genes 0.000 description 3
• 108090000663 Annexin A1 Proteins 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 3
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
• 108091035710 E-box Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
• 206010021263 IgA nephropathy Diseases 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 241001142635 Lema Species 0.000 description 3
• 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 3
• 101000980580 Mus musculus Mast cell protease 1 Proteins 0.000 description 3
• 208000013901 Nephropathies and tubular disease Diseases 0.000 description 3
• 206010029379 Neutrophilia Diseases 0.000 description 3
• 208000002151 Pleural effusion Diseases 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010037394 Pulmonary haemorrhage Diseases 0.000 description 3
• 101000777393 Rattus norvegicus C-C motif chemokine 2 Proteins 0.000 description 3
• 206010067739 Shrinking lung syndrome Diseases 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• 239000006180 TBST buffer Substances 0.000 description 3
• 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 210000003651 basophil Anatomy 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 229920002988 biodegradable polymer Polymers 0.000 description 3
• 239000004621 biodegradable polymer Substances 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 230000005779 cell damage Effects 0.000 description 3
• 208000037887 cell injury Diseases 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000012937 correction Methods 0.000 description 3
• 238000009295 crossflow filtration Methods 0.000 description 3
• 238000007405 data analysis Methods 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
• 230000003292 diminished effect Effects 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 3
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 3
• 210000003904 glomerular cell Anatomy 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• 201000008269 immune-complex glomerulonephritis Diseases 0.000 description 3
• 230000001861 immunosuppressant effect Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 210000002570 interstitial cell Anatomy 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000012933 kinetic analysis Methods 0.000 description 3
• 210000005240 left ventricle Anatomy 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 238000013425 morphometry Methods 0.000 description 3
• 210000003097 mucus Anatomy 0.000 description 3
• 230000030505 negative regulation of chemotaxis Effects 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
• 230000000737 periodic effect Effects 0.000 description 3
• 150000008300 phosphoramidites Chemical class 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 239000004627 regenerated cellulose Substances 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 210000005241 right ventricle Anatomy 0.000 description 3
• 238000011808 rodent model Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 210000004881 tumor cell Anatomy 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 239000012224 working solution Substances 0.000 description 3
• ROICYBLUWUMJFF-RDTXWAMCSA-N (6aR,9R)-N,7-dimethyl-N-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound CN(C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=CC=CC(C2=C1)=C34)C(C)C ROICYBLUWUMJFF-RDTXWAMCSA-N 0.000 description 2
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 102000004145 Annexin A1 Human genes 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
• 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
• 108700013048 CCL2 Proteins 0.000 description 2
• 101150083327 CCR2 gene Proteins 0.000 description 2
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
• 244000304337 Cuminum cyminum Species 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
• 201000009273 Endometriosis Diseases 0.000 description 2
• 229940118365 Endothelin receptor antagonist Drugs 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 2
• 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
• 102000003839 Human Proteins Human genes 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 229920001202 Inulin Polymers 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000282560 Macaca mulatta Species 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 108010079855 Peptide Aptamers Proteins 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 206010038540 Renal tubular necrosis Diseases 0.000 description 2
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 208000000924 Right ventricular hypertrophy Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 150000003838 adenosines Chemical class 0.000 description 2
• 102000030621 adenylate cyclase Human genes 0.000 description 2
• 108060000200 adenylate cyclase Proteins 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 238000002399 angioplasty Methods 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 230000004872 arterial blood pressure Effects 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
• 239000004327 boric acid Substances 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000002556 chemokine receptor agonist Substances 0.000 description 2
• 239000002559 chemokine receptor antagonist Substances 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000010339 dilation Effects 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000002308 endothelin receptor antagonist Substances 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 230000001435 haemodynamic effect Effects 0.000 description 2
• 230000000004 hemodynamic effect Effects 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 102000043805 human CCL8 Human genes 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 201000006334 interstitial nephritis Diseases 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 229940029339 inulin Drugs 0.000 description 2
• 238000009588 inulin clearance Methods 0.000 description 2
• 238000011862 kidney biopsy Methods 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 150000002617 leukotrienes Chemical class 0.000 description 2
• 238000012417 linear regression Methods 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 210000003584 mesangial cell Anatomy 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000002777 nucleoside Substances 0.000 description 2
• 125000003835 nucleoside group Chemical group 0.000 description 2
• 201000002674 obstructive nephropathy Diseases 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 230000002028 premature Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 150000003180 prostaglandins Chemical class 0.000 description 2
• 230000004088 pulmonary circulation Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 231100001028 renal lesion Toxicity 0.000 description 2
• 238000004153 renaturation Methods 0.000 description 2
• 230000019254 respiratory burst Effects 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 239000012898 sample dilution Substances 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 210000002437 synoviocyte Anatomy 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 210000004926 tubular epithelial cell Anatomy 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 238000009736 wetting Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
• CGTZMJIMMUNLQD-STYNFMPRSA-N (2r)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CGTZMJIMMUNLQD-STYNFMPRSA-N 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
• BALXSYQWXWVVJJ-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;phosphoric acid Chemical compound OP(O)(O)=O.O=C1NC(N)=NC2=C1NC=N2 BALXSYQWXWVVJJ-UHFFFAOYSA-N 0.000 description 1
• PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
• WASZXVMLVDQNDE-UHFFFAOYSA-N 3-[(3-aminopropyl)amino]-4-hydroxybenzoic acid Chemical compound NCCCNC=1C=C(C(=O)O)C=CC=1O WASZXVMLVDQNDE-UHFFFAOYSA-N 0.000 description 1
• GXGKKIPUFAHZIZ-UHFFFAOYSA-N 5-benzylsulfanyl-2h-tetrazole Chemical compound C=1C=CC=CC=1CSC=1N=NNN=1 GXGKKIPUFAHZIZ-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 206010059245 Angiopathy Diseases 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 102100040006 Annexin A1 Human genes 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 101000897479 Bos taurus C-C motif chemokine 2 Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
• 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
• 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• 101150111331 CCL5 gene Proteins 0.000 description 1
• 102000004499 CCR3 Receptors Human genes 0.000 description 1
• 108010017316 CCR3 Receptors Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 102000004325 CX3C Chemokines Human genes 0.000 description 1
• 108010081635 CX3C Chemokines Proteins 0.000 description 1
• 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
• 229940082432 Chemokine receptor agonist Drugs 0.000 description 1
• 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000029147 Collagen-vascular disease Diseases 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 241001268392 Dalla Species 0.000 description 1
• 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 108010067770 Endopeptidase K Proteins 0.000 description 1
• LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 1
• 101000897485 Equus caballus C-C motif chemokine 2 Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 206010015719 Exsanguination Diseases 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
• 241000855538 Gallacea scleroderma Species 0.000 description 1
• 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
• 101150112014 Gapdh gene Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000001828 Gelatine Substances 0.000 description 1
• 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
• 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
• 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
• 101100438769 Homo sapiens CCL8 gene Proteins 0.000 description 1
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
• 101100023378 Homo sapiens MIF gene Proteins 0.000 description 1
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
• 101000826116 Homo sapiens Single-stranded DNA-binding protein 3 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 206010021133 Hypoventilation Diseases 0.000 description 1
• GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
• 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 102100035304 Lymphotactin Human genes 0.000 description 1
• 102100037611 Lysophospholipase Human genes 0.000 description 1
• 229940123313 MCP-1 antagonist Drugs 0.000 description 1
• 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 208000020128 Mitral stenosis Diseases 0.000 description 1
• 101100328542 Mus musculus C3 gene Proteins 0.000 description 1
• 101100274524 Mus musculus Clec18a gene Proteins 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 102000019040 Nuclear Antigens Human genes 0.000 description 1
• 108010051791 Nuclear Antigens Proteins 0.000 description 1
• 230000004989 O-glycosylation Effects 0.000 description 1
• DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 101150044568 PRNP gene Proteins 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000004362 Penile Induration Diseases 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 208000020758 Peyronie disease Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
• 108010058864 Phospholipases A2 Proteins 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 241001499740 Plantago alpina Species 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 208000021060 Pulmonary arterial hypertension associated with another disease Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 206010037867 Rash macular Diseases 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 206010039163 Right ventricular failure Diseases 0.000 description 1
• WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 102100023008 Single-stranded DNA-binding protein 3 Human genes 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 206010041660 Splenomegaly Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 206010061372 Streptococcal infection Diseases 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 230000006043 T cell recruitment Effects 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 108010067369 acetylpolyamine amidohydrolase Proteins 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 210000004712 air sac Anatomy 0.000 description 1
• 230000036428 airway hyperreactivity Effects 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 208000028004 allergic respiratory disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001745 anti-biotin effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 238000002869 basic local alignment search tool Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 239000012148 binding buffer Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
• 229960003065 bosentan Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 238000011262 co‐therapy Methods 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 150000001945 cysteines Chemical group 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000000779 depleting effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 150000002066 eicosanoids Chemical class 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 230000010102 embolization Effects 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 208000028208 end stage renal disease Diseases 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000004887 epithelial permeability Effects 0.000 description 1
• 230000008508 epithelial proliferation Effects 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 229940073579 ethanolamine hydrochloride Drugs 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000009454 functional inhibition Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000002695 general anesthesia Methods 0.000 description 1
• 210000000585 glomerular basement membrane Anatomy 0.000 description 1
• 210000002601 glomerular mesangium Anatomy 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 150000002303 glucose derivatives Chemical class 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
• 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
• 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
• 230000036732 histological change Effects 0.000 description 1
• 102000044446 human CD46 Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 210000002861 immature t-cell Anatomy 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000005931 immune cell recruitment Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 229940099472 immunoglobulin a Drugs 0.000 description 1
• 230000002625 immunotoxic effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011503 in vivo imaging Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 210000002074 inflammatory monocyte Anatomy 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 235000013902 inosinic acid Nutrition 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002634 lipophilic molecules Chemical class 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 230000005823 lung abnormality Effects 0.000 description 1
• 239000002932 luster Substances 0.000 description 1
• 108010019677 lymphotactin Proteins 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 231100000855 membranous nephropathy Toxicity 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 208000006887 mitral valve stenosis Diseases 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 238000007491 morphometric analysis Methods 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000003589 nefrotoxic effect Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
• 231100000381 nephrotoxic Toxicity 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 231100000957 no side effect Toxicity 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 208000014055 occupational lung disease Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229960002275 pentobarbital sodium Drugs 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920002721 polycyanoacrylate Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1
• 230000030786 positive chemotaxis Effects 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 1
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
• 229960003081 probenecid Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
• 150000003815 prostacyclins Chemical class 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• 230000036593 pulmonary vascular resistance Effects 0.000 description 1
• 210000003492 pulmonary vein Anatomy 0.000 description 1
• 230000006825 purine synthesis Effects 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical class C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 1
• 229930002356 pyrrolizidine alkaloid Natural products 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 201000004335 respiratory allergy Diseases 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229940071089 sarcosinate Drugs 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 238000012764 semi-quantitative analysis Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
• 239000011122 softwood Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000007939 sustained release tablet Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 206010042772 syncope Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009392 systemic autoimmunity Effects 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 238000005353 urine analysis Methods 0.000 description 1
• 230000006496 vascular abnormality Effects 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 208000037997 venous disease Diseases 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 229930195724 β-lactose Natural products 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1